close
close
Exact sciences emphasize innovations in the detection and precision succology of early cancer at ASCO 2025.

Exact sciences emphasize innovations in the detection and precision succology of early cancer at ASCO 2025.

by

Madison, Wis., May 22, 2025. Multi-Cancer Early identification test (MCCE), the Oncotype DX Breast Recurrence Score® test and the Cologuard® test, which underlines the expanding portfolio and the commitment of exact sciences through scientific excellence for the promotion of care.

“The data of the exact sciences at ASCO 2025 reflect the scientific accuracy and clinical importance of our expanding portfolio and our pipeline,” said Dr. Rick Baeher, Chief Medical Officer, Precision Oncology at Exact Sciences. “From the MRD to MCED to CRC screening, we promote evidence-based innovations that help strengthen the patient to strengthen the provider and provide decisive answers to patients. Every study, partnership and data point move closer to a future in which cancer is discovered earlier and treated with greater accuracy.”

Real-world evidence that support the cologian test continues to grow, with continuous studies for repeat screening. New data from prominent experts and research groups reinforce the Onkotype-DX® test as a trustworthy, demonstrably supported instrument and confirm its role as standard for predicting chemotherapy benefits for breast cancer patients. Building on more than a decade experience with Cologuard and 20 years of leadership with the Oncotype DX test, the exact science continues to promote the future of precision oncology and the screening of several cancer.

New data and continuous generation generation underline the authority of the Oncodetect test to recognize the recurrence of cancer. Data from the BETA CORRECT study strengthen the clinical basis of the Oncodetekt test1. The expansion of this evidence to several solid tumor species, exact sciences and Flatiron Health The registration in a multi-year study that evaluates how MRD tests can improve the surveillance and treatment decisions in the community in community care.

New data support the promise of MCED as exact sciences that prepare for the LDT start. A modeling study showed that an annual MCCE test could reduce the incidence of the late stage by more than 40% and the mortality in groups with high risk by up to 18%2. In addition, the Falcon Registry, a large, prospective real study on the MCCED test from Exact Sciences, will pursue 25,000 participants against a 50,000-person standard-car core in order to evaluate adoption, the results and the patient experience. In the exact sciences on the Start Cancerguard ™ ex, its McED-Labor-developed test (LDT), these findings are prepared in the second half of the year, which is a significant step towards expanding access to earlier cancer detection.

Leave a Comment